Inhibition of the Ras/Raf/MEK/ERK and RET Kinase Pathways with the Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Medullary and Differentiated Thyroid Malignancies

PURPOSE: Ras/Raf/MAPK kinase/ERK and rearranged in transformation (RET) kinase pathways are important in thyroid cancer. We tested sorafenib, a B-Raf, RET, and vascular endothelial growth factor receptor kinase inhibitor, combined with tipifarnib, a farnesyltransferase inhibitor that inactivates Ras...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Hong, David S., Cabanillas, Maria E., Wheler, Jennifer, Naing, Aung, Tsimberidou, Apostolia M., Ye, Lei, Waguespack, Steven G., Hernandez, Mike, El Naggar, Alder K., Bidyasar, Savita, Wright, John, Sherman, Steven I., Kurzrock, Razelle
Format: Artigo
Sprog:Inglês
Udgivet: Endocrine Society 2011
Fag:
Endocrine Care
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3070247/
https://ncbi.nlm.nih.gov/pubmed/21289252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2010-1899
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker